Serplulimab Combined With CCRT for LS-SCLC.

NCT06295926 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Serplulimab

Sponsor

Peking Union Medical College Hospital